UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029095
Receipt number R000033280
Scientific Title A study to evaluate effects of daily food containing plant extracts on chronic inflammation in an adult subject
Date of disclosure of the study information 2017/09/11
Last modified on 2019/11/07 10:50:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to evaluate effects of daily food containing plant extracts on chronic inflammation in an adult subject

Acronym

Effects of plant extracts on chronic inflammation in an adult subject

Scientific Title

A study to evaluate effects of daily food containing plant extracts on chronic inflammation in an adult subject

Scientific Title:Acronym

Effects of plant extracts on chronic inflammation in an adult subject

Region

Japan


Condition

Condition

N/A

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study examine the effect of 12-weeks ingestion of a food containing plant extracts for improving chronic inflammation in an adult males and females.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

At 0, 4, 8, 12 weeks in the intervention
(1) C-reactive protein (CRP)
(2) Tumor necrosis factor (TNF)-alpha
(3) Interleukin (IL)-6
(4) Interleukin (IL)-1beta
(5) Soluble vascular cell adhesion molecule-1 (sVCAM-1)

Key secondary outcomes

At 0, 4, 8, 12 weeks in the intervention
(1) Hemoglobin A1c (HbA1c)
(2) Uric acid (UA)
(3) Malondialdehyde modified LDL (MDA-LDL)
(4) Urinary 8-Hydroxydeoxyguanosine (8-OHdG)
(5) Flow mediated dilation (FMD)
(6) Reactive hyperemia peripheral arterial tonometry (RH-PAT; At 0, 12 weeks in the intervention)
(7) Acceleration plethysmogram
(8) Profile of mood states-2nd edition (POMS-2) short versions
(9) MOS 36-Item short form version 2 (SF-36v2; acute)
(10) Visual analogue scale (VAS)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Oral ingestion of the test product with a plant extract (3 tablets per a day; 12 weeks)

Interventions/Control_2

Oral ingestion of the test product without a plant extract (3 tablets per a day; 12 weeks)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

69 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) An adult males and females from 50 to 69 years of age
(2) Subjects whose BMI values are between normal-high and obesity class 1 (>=23 and <30) or blood pressure are between normal and grade 1 hypertension (systolic blood pressure (SBP); >=120 and 160< or diastolic blood pressure (DBP); 80>= and 100<)
(3) Subjects who do not have any problem such as arm numbness during measurement of endothelial function
(4) Subjects who participate in this study with a written informed consent.

Key exclusion criteria

(1) Subjects whose HCV antibody or HbsAg are positive
(2) Subjects who consecutively intake pharmaceutical or healthcare food which is possible to influence the result of this study
(3) Subjects who have a history of heart disease, liver disease, kidney, or digestive system disease
(4) Subjects who have a history of cardiovascular disease
(5) Subjects who have excessive alcohol-drinking or smoking habit
(6) Subjects who have extremely irregular dietary habits
(7) Subjects who have medication or food allergy
(8) Subjects who are participating in other trial, have participated in the past 4 weeks, or plan to participate in other trial during scheduled period in this trial
(9) Subjects who have made a blood donation within the last one month prior to this study
(10) Male subjectss who have made a blood donation of 400 mL within the last three months prior to this study
(11) Female subjects who have made a blood donation of 400 mL within the last four months prior to this study
(12) Male subjects who have made a blood donation over an amout (1,200 mL minus the estimated volume of blood sampling during the study) within the last one year prior to this study
(13) Female subjects who have made a blood donation over an amout (800 mL minus the estimated volume of blood sampling during the study) within the last one year prior to this study
(14) Subjects judged as unsuitable for the study by the investigators

Target sample size

90


Research contact person

Name of lead principal investigator

1st name Yoshihiro
Middle name
Last name Yamamoto

Organization

House Wellness Foods Corporation

Division name

Research and Development Institute

Zip code

664-0011

Address

Imoji 3-20, Itami, Hyogo

TEL

072-778-1121

Email

Yamamoto_Yoshihiro@house-wf.co.jp


Public contact

Name of contact person

1st name Ryusei
Middle name
Last name Uchio

Organization

House Wellness Foods Corporation

Division name

Research and Development Institute

Zip code

664-0011

Address

Imoji 3-20, Itami, Hyogo

TEL

072-778-1127

Homepage URL


Email

Uchio_Ryusei@house-wf.co.jp


Sponsor or person

Institute

House Wellness Foods Corporation Research and Development Institute

Institute

Department

Personal name



Funding Source

Organization

House Wellness Foods Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of the Chiyoda Paramedical Care Clinic

Address

3-3-5 Uchikanda, Chiyoda-ku, Tokyo, Japan

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 09 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 09 Month 08 Day

Date of IRB

2017 Year 08 Month 24 Day

Anticipated trial start date

2017 Year 09 Month 12 Day

Last follow-up date

2017 Year 12 Month 12 Day

Date of closure to data entry

2018 Year 01 Month 24 Day

Date trial data considered complete

2018 Year 02 Month 08 Day

Date analysis concluded

2018 Year 03 Month 30 Day


Other

Other related information



Management information

Registered date

2017 Year 09 Month 11 Day

Last modified on

2019 Year 11 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033280


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name